[Long-term effects of HBV treatment Peg-IFN alfa-2a alone or combined with lamivudine].

The long-term outcomes showed a special place of IFN alfa-2a in therapy of chronic hepatitis B. Multivariate analysis revealed that patients who received 48 weeks treatment PegIFN-alfa-2a with reduction of serum ALT level and suppression of HBV-DNA replication will have a chance to keep this effect in the future. The results of long term follow-up showed that IFN alfa-2a improves prognosis in terms of reduction of progression to cirrhosis and hepatocellular carcinoma.